Related Experiment Videos
Hepatotoxicity and nelfinavir: a meta-analysis
Raffaele Bruno1, Paolo Sacchi, Laura Maiocchi
1Division of Infectious and Tropical Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Mateo Hospital--University of Pavia, Italy.
Summary
Nelfinavir and indinavir show the lowest rates of severe liver damage among protease inhibitors used for HIV-1 treatment. This finding is significant, especially for patients with co-existing hepatitis virus infections.
Area of Science:
- Pharmacology
- Hepatology
- Virology
Background:
- Highly active antiretroviral therapy (HAART) including protease inhibitors has improved survival for HIV-1 patients.
- Drug-induced hepatotoxicity is a significant concern, particularly in patients with viral hepatitis co-infection.
- Nelfinavir is a commonly used first-line protease inhibitor due to its clinical profile and resistance patterns.
Purpose of the Study:
- To compare the relative risk of hepatotoxicity among different protease inhibitors.
- To evaluate nelfinavir's hepatotoxicity potential compared to other protease inhibitors.
Main Methods:
- An exploratory meta-analysis was performed.
- Data from 4268 patients across 3 clinical trials and 1 cohort study were analyzed.
- Liver enzyme level increases were the primary outcome measure.
Main Results:
- Nelfinavir (2.9%) and indinavir (3.1%) demonstrated the lowest rates of severe hepatotoxicity among tested protease inhibitors.
- This low rate of hepatotoxicity for nelfinavir was observed even in patients co-infected with hepatitis viruses.
- Significant differences in hepatotoxicity potential exist among commercially available protease inhibitors.
Conclusions:
- Protease inhibitors exhibit varying potentials for causing hepatotoxicity.
- Nelfinavir appears to have a favorable safety profile regarding liver toxicity.
- These findings support careful selection of protease inhibitors based on individual patient profiles, especially those with viral hepatitis co-infections.